Signaturefd LLC Sells 10,326 Shares of Qiagen N.V. (NYSE:QGEN)

Signaturefd LLC lowered its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 75.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,354 shares of the company's stock after selling 10,326 shares during the period. Signaturefd LLC's holdings in Qiagen were worth $135,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. grew its position in Qiagen by 3.6% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company's stock worth $438,000 after buying an additional 341 shares in the last quarter. Pitcairn Co. grew its holdings in shares of Qiagen by 5.3% during the 4th quarter. Pitcairn Co. now owns 6,996 shares of the company's stock worth $312,000 after purchasing an additional 354 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of Qiagen by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares during the period. Headlands Technologies LLC raised its stake in Qiagen by 2.0% in the fourth quarter. Headlands Technologies LLC now owns 19,823 shares of the company's stock valued at $883,000 after purchasing an additional 397 shares in the last quarter. Finally, LPL Financial LLC lifted its position in Qiagen by 2.6% during the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after purchasing an additional 432 shares during the period. Institutional investors own 70.00% of the company's stock.

Qiagen Stock Performance

Shares of Qiagen stock opened at $48.35 on Monday. Qiagen N.V. has a 52 week low of $37.63 and a 52 week high of $49.30. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40. The business has a 50 day moving average price of $45.95 and a 200-day moving average price of $42.98. The company has a market cap of $10.75 billion, a PE ratio of 121.23, a price-to-earnings-growth ratio of 2.46 and a beta of 0.68.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The business had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. Qiagen's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.44 EPS. Equities analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Dividend Announcement

The business also recently declared a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen's payout ratio is currently 62.50%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on QGEN shares. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Robert W. Baird upped their price objective on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Bank of America upped their target price on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Finally, Barclays initiated coverage on shares of Qiagen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $49.40.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.